| NCT05979857 | Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma | NOT_YET_RECRUITING | EARLY_PHASE1 | 2024-03-15 | 2027-08-15 | 2025-08-15 |
| NCT05266196 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | ENROLLING_BY_INVITATION | PHASE1, PHASE2 | 2022-01-15 | 2025-12 | 2025-12 |
| NCT03895684 | Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2019-06-25 | 2021-04-13 | 2021-04-13 |
| NCT03600649 | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | ACTIVE_NOT_RECRUITING | PHASE1 | 2018-06-04 | 2025-12 | 2025-09 |